Join Growin Stock Community!
Beta
Back to AIDX.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
revenue-chart

AIDX Revenue

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

20/20 biolabs, inc. common stock (AIDX) 2025 financial report shows revenue of 2.05M USD, with a YoY growth rate of 16.71%. This data clearly demonstrates significant revenue growth, with the company showing strong operational momentum and a marked increase in market demand. To fully capture future growth potential and investment opportunities, investors should closely monitor 20/20 biolabs, inc. common stock (AIDX)’s upcoming financial reports and key strategic adjustments, and leverage diversified data analysis, especially advanced tools like Growin AI Value Analysis, for a comprehensive and forward-looking evaluation.